John Glenn - 20 Jun 2026 Form 4 Insider Report for IRADIMED CORP (IRMD)

Reporting relationship: CFO
Issuer ticker: IRMD
Reported as of: 20 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 09:29:05 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John Glenn

Key filing fact

John Glenn filed Form 4 for IRADIMED CORP (IRMD) on 23 Jun 2026.

Key facts

This page summarizes John Glenn's Form 4 filing for IRADIMED CORP (IRMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2026, 09:29.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001253497 Primary reporting owner

GLENN JOHN

Relationship: CFO
Address: C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO
Signature: /s/ John Glenn
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,796
Change %: +69%
Price
Shares after: 14,256
Date: 20 Jun 2026
Ownership: Direct
Footnotes: F1

IRMD transaction

Common Stock

Tax liability

Transaction value
Shares: -2,319
Change %: -16%
Price: $92.20^*
Shares after: 11,937
Date: 20 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRMD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -5,796
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 20 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,796
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

Footnote F2

The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 30, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.